Anrotinib is a multi-targeted small molecule targeted drug, with less drug side effects, but the specific resistance time is not easy to determine, about one year, and the effect should be observed at any time according to the treatment situation. Some patients with Anrotinib may have poorer results after six months and need to switch to other regimens or chemotherapy again. Anrotinib is mainly used for third-line targeted therapy for non-small cell lung cancer, but of course, other malignant tumors such as soft tissue sarcoma and small cell lung cancer are also indications for Anrotinib. In addition, the clinical treatment of gastric cancer and pancreatic cancer is also applied to the treatment of Anrotinib. It is not easy to determine the specific efficacy, but only to try to use it.